-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Crescent Biopharma, Lowers Price Target to $32

Benzinga·11/13/2026 15:55:38
Listen to the news
Piper Sandler analyst Biren Amin maintains Crescent Biopharma (NASDAQ:CBIO) with a Overweight and lowers the price target from $35 to $32.